Avalon Ventures
VC Fund
La Jolla, United States
Avalon Ventures is an early stage venture capital fund focused on information technology and life sciences.
- Total investments:
- 169
- Last investment:
- Lead investor:
- 33%
- Fund size:
- $135M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Avalon Ventures invests in
Stages Avalon Ventures invests in
Countries Avalon Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $2.2M–$20M
- Series B
- $5M–$34M
Investment Focus
Industry
- Software 22 (13%)
- Health Care 20 (12%)
- Biotechnology 19 (11%)
- Enterprise Software 12 (7%)
- Mobile 11 (7%)
Stage
- Series A 49 (29%)
- Series B 34 (20%)
- Seed 18 (11%)
- Funding Round 13 (8%)
- Series C 10 (6%)
Country
- United States 80 (47%)
- United Kingdom 2 (1%)
- Denmark 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Court Turner
Venture Partner
|
Venture Partner | Total investments: 2 | Find email | |
Kevin Kinsella
Founder and Managing Director
|
Founder and Managing Director | Total investments: 7 | Find email | |
Steve Tomlin
Managing Member
|
Managing Member | Total investments: 2 | Find email | |
Brady Bohrmann
Managing Member
|
Managing Member | Total investments: 29 | Find email | |
Richard Levandov
Partner
|
Partner | Total investments: 48 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Enlaza Therapeutics is a biotechnology research company. It was founded in 2020 and is headquartered in La Jolla, California. | $100M / Series A / Apr 30, 2024 | ||
| Vocera provides mobile communication solutions addressing critical communication challenges facing hospitals today. They help their customers improve patient safety and satisfaction, and increase hospital efficiency and productivity through their Voice Communication solution, Secure Messaging applications and Care Transition solutions. Exclusivelyendorsed by the American Hospital Association, the Vocera solutions are installed in more than 800 hospitals and healthcare facilities worldwide. The company is headquartered in San Jose, Calif., with offices in Tennessee, Canada and the United Kingdom. | $8M / Post-IPO Equity / May 08, 2023 | ||
| Jnana Therapeutics is a biotechnology company focused on discovering and developing medicines that improve patient lives. Utilizing its RAPID platform, the firm accelerates the identification of therapeutic targets and the creation of small molecule therapies for various diseases. Jnana aims to enhance drug discovery efficiency through advancedchemoproteomics techniques, addressing unmet medical needs. | $107M / Series C / Nov 15, 2022 | ||
| Enlaza Therapeutics is a biotechnology research company. It was founded in 2020 and is headquartered in La Jolla, California. | $61M / Seed / Oct 12, 2022 | ||
| Joy is a wedding company that gives couples a smarter way to plan their big day. Using Joy, couples can create a beautifully-designed wedding website and mobile app, build their All-in-One Registry, manage guest lists and RSVPs, send online or printed Save the Dates, invitations and eCards, provide travel and accommodations options for guests, hostvirtual wedding events, create a shared virtual wedding album and virtual guest book, and more. Wedding guests can purchase registry gifts, book travel plans and accommodations, get directions to wedding events via a Google Maps integration, order a ride to wedding events via ride-sharing integrations, add wedding events to their calendar with a click, and more.Based in San Francisco, Joy launched in 2016 through Y Combinator. Visit withjoy.com and follow @withjoy to see why couples around the world are planning their weddings with Joy. | $20M / Series A / Sep 01, 2021 | ||
| Jnana Therapeutics is a biotechnology company focused on discovering and developing medicines that improve patient lives. Utilizing its RAPID platform, the firm accelerates the identification of therapeutic targets and the creation of small molecule therapies for various diseases. Jnana aims to enhance drug discovery efficiency through advancedchemoproteomics techniques, addressing unmet medical needs. | $50M / Series B / Aug 18, 2021 | ||
| Primer is an internet company that helps companies understand massive stores of text data using AI. It uses machine learning techniques to help parse and collate a large number of documents across several languages in order to facilitate further investigation. It was founded in 2015 and headquartered in San Francisco, California. | $110M / Series C / Jun 22, 2021 | ||
| Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response. | $125M / Series B / Apr 20, 2021 | ||
| Fortis Therapeutics is immuno-oncology biotech focused on developing new antibody-drug conjugate therapies against CD46 for the treatment of late-stage multiple myeloma and late-stage prostate cancer and other indications. | $40M / Series A / Mar 29, 2021 | ||
| Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response. | $56M / Series A / Mar 03, 2021 | ||
| See all 169 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Avalon Ventures invest in?
Avalon Ventures invests primarily in Software, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 169 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Avalon Ventures's check size?
Avalon Ventures typically joins rounds of $2.2M–$20M at Series A and $5M–$34M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Avalon Ventures participates in.
How do I contact Avalon Ventures?
Public channels for Avalon Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Avalon Ventures?
The team at Avalon Ventures includes Court Turner (Venture Partner), Kevin Kinsella (Founder and Managing Director) and Steve Tomlin (Managing Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
